PMID- 37813647
OWN - NLM
STAT- MEDLINE
DCOM- 20231211
LR  - 20240319
IS  - 1347-7439 (Electronic)
IS  - 0916-7250 (Print)
IS  - 0916-7250 (Linking)
VI  - 85
IP  - 12
DP  - 2023 Dec 6
TI  - Safety and pharmacokinetics of thalidomide in tumor-bearing dogs.
PG  - 1261-1268
LID - 10.1292/jvms.23-0200 [doi]
AB  - Thalidomide, an angiogenesis inhibitor, has recently been used to treat malignant 
      canine tumors. This study retrospectively investigated the adverse events (AEs) 
      of thalidomide administered to tumor-bearing dogs. We investigated the 
      pharmacokinetics of thalidomide after administration and the rate of body weight 
      change before and after administration. The initial thalidomide dose was 5 mg/kg 
      per os once daily, which was increased to 10 mg/kg once daily in dogs with no 
      significant AEs. Pharmacokinetics were measured in four dogs after the 5 mg/kg or 
      10 mg/kg dose. We evaluated AEs related to clinical signs in 51 patients; 9/51 
      had lethargy, 6/51 had tremor, 4/51 had dizziness, 31/51 had decreased appetite, 
      8/51 had vomiting, and 16/49 had soft stool/diarrhea. We evaluated hematologic 
      toxicity in 44 patients with grade 3 or higher adverse events; 1/44 had 
      thrombocytopenia, 1/44 had increased blood urea nitrogen concentrations, and 5/44 
      had increased alanine aminotransferase activities. The mean thalidomide blood 
      levels were C(max)=1.4 +/- 0.7 mug/mL (Area under the curve [AUC](0-24)=8.5 +/- 4.7 
      mug*hr /mL) and C(max)=3.2 +/- 2.1 mug/mL (AUC(0-24)=22.0 +/- 14.7 mug*hr/mL) in the 5 
      mg/kg and 10 mg/kg groups, respectively. The C(max) and AUC in the 10 mg/kg group 
      were comparable to the effective blood concentrations seen in humans administered 
      thalidomide. The weight fluctuation rates were assessed in 24 dogs approximately 
      1 month after the start of thalidomide administration; more than half showed 
      weight maintenance or gain. Most AEs were clinically acceptable; however, 
      peripheral nerve signs were seen in some dogs.
FAU - Matsuyama, Fukiko
AU  - Matsuyama F
AD  - Japan Small Animal Cancer Center, Saitama, Japan.
FAU - Fujita, Yukiyoshi
AU  - Fujita Y
AD  - Gunma Prefectural Cancer Center, Gunma, Japan.
FAU - Fukazawa, Eri
AU  - Fukazawa E
AD  - Japan Small Animal Cancer Center, Saitama, Japan.
FAU - Kobayashi, Tetsuya
AU  - Kobayashi T
AD  - Japan Small Animal Cancer Center, Saitama, Japan.
LA  - eng
PT  - Journal Article
DEP - 20231010
PL  - Japan
TA  - J Vet Med Sci
JT  - The Journal of veterinary medical science
JID - 9105360
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 0 (Angiogenesis Inhibitors)
SB  - IM
MH  - Humans
MH  - Dogs
MH  - Animals
MH  - Thalidomide/adverse effects
MH  - Retrospective Studies
MH  - Angiogenesis Inhibitors
MH  - *Neoplasms/drug therapy/veterinary
MH  - Area Under Curve
MH  - *Dog Diseases/drug therapy/chemically induced
PMC - PMC10788173
OTO - NOTNLM
OT  - adverse event
OT  - malignant tumor
OT  - pharmacokinetics
OT  - thalidomide
COIS- None of the authors of this paper have any financial or personal relationships 
      that could inappropriately influence or bias the content of the paper.
EDAT- 2023/10/10 00:42
MHDA- 2023/12/11 12:43
PMCR- 2023/12/01
CRDT- 2023/10/09 21:43
PHST- 2023/12/11 12:43 [medline]
PHST- 2023/10/10 00:42 [pubmed]
PHST- 2023/10/09 21:43 [entrez]
PHST- 2023/12/01 00:00 [pmc-release]
AID - 23-0200 [pii]
AID - 10.1292/jvms.23-0200 [doi]
PST - ppublish
SO  - J Vet Med Sci. 2023 Dec 6;85(12):1261-1268. doi: 10.1292/jvms.23-0200. Epub 2023 
      Oct 10.